Arcutis Biotherapeutics

Commercial-stage medical dermatology company anchored by ZORYVE (roflumilast), a topical PDE4 inhibitor approved in cream and foam formulations for plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. Pipeline expands ZORYVE into adjacent indications (vitiligo, hidradenitis suppurativa) and adds non-PDE4 candidates ARQ-252 (topical JAK1) and ARQ-234 (CD200R agonist) in atopic dermatitis.